- Home
- ACRV vs GRCE Comparison
ACRV vs GRCE Comparison
Compare ACRV & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- GRCE
- Stock Information
- Founded
- ACRV 2018
- GRCE 2002
- Country
- ACRV United States
- GRCE United States
- Employees
- ACRV N/A
- GRCE N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- GRCE
- Sector
- ACRV Health Care
- GRCE
- Exchange
- ACRV Nasdaq
- GRCE NYSE
- Market Cap
- ACRV 40.4M
- GRCE 42.1M
- IPO Year
- ACRV 2022
- GRCE N/A
- Fundamental
- Price
- ACRV $1.34
- GRCE $3.39
- Analyst Decision
- ACRV Buy
- GRCE Strong Buy
- Analyst Count
- ACRV 7
- GRCE 1
- Target Price
- ACRV $17.60
- GRCE $12.00
- AVG Volume (30 Days)
- ACRV 379.9K
- GRCE 59.2K
- Earning Date
- ACRV 08-12-2025
- GRCE 08-15-2025
- Dividend Yield
- ACRV N/A
- GRCE N/A
- EPS Growth
- ACRV N/A
- GRCE N/A
- EPS
- ACRV N/A
- GRCE N/A
- Revenue
- ACRV N/A
- GRCE N/A
- Revenue This Year
- ACRV N/A
- GRCE N/A
- Revenue Next Year
- ACRV N/A
- GRCE N/A
- P/E Ratio
- ACRV N/A
- GRCE N/A
- Revenue Growth
- ACRV N/A
- GRCE N/A
- 52 Week Low
- ACRV $1.05
- GRCE $1.75
- 52 Week High
- ACRV $10.16
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- ACRV 55.88
- GRCE N/A
- Support Level
- ACRV $1.15
- GRCE N/A
- Resistance Level
- ACRV $1.38
- GRCE N/A
- Average True Range (ATR)
- ACRV 0.09
- GRCE 0.00
- MACD
- ACRV 0.02
- GRCE 0.00
- Stochastic Oscillator
- ACRV 83.33
- GRCE 0.00
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.